Skip to main content
SpringerLink
Log in

The Genomics of Elevated ALT and Adducts in Therapeutic Acetaminophen Treatment: a Pilot Study

  • Original Article
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Introduction

Therapeutic acetaminophen (APAP) ingestion causes asymptomatic drug–induced liver injury in some patients. In most cases, elevations in alanine aminotransferase (ALT) are transient and return to the normal range, even with continued APAP ingestion, though ALT elevation persists in some patients unpredictably. The etiology of this liver injury or adaption is unclear. Our objective was to identify new pharmacogenomic variants associated with elevated ALT or elevated protein adduct concentrations in patients receiving therapeutic acetaminophen.

Methods

We performed genome-wide sequencing analysis on eight patients using leftover blood samples from an observational study that administered four grams of acetaminophen for up to 16 days to all patients. Two patients with ALT elevations > two times the upper limit of normal, two patients with no adduct formation, and four control patients were sequenced. The genomes were aligned with the GRCh38 reference sequence, and variants with predicted low, moderate, or high impact on the subsequent proteins were first manually curated for biologic plausibility, then organized and examined in the REACTOME pathway analysis program.

Results

We found 394 variants in 107 genes associated with elevated ALT. Variants associated with ALT elevation predominantly involved genes in the immune system (MHC class II complex genes), endoplasmic reticulum stress response (SEC23B and XBP1), oxidative phosphorylation (NDUFB9), and WNT/beta-catenin signaling (FZD5). Variants associated with elevated adducts were primarily in signal transduction (MUC20) and DNA repair mechanisms (P53).

Conclusions

While underpowered, genetic variants in immune system genes may be associated with drug-induced liver injury at therapeutic doses of acetaminophen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93.

    Article  CAS  Google Scholar 

  2. Heard K, Green JL, Anderson V, Bucher-Bartelson B, Dart RC. A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacol Toxicol. 2014;15:39.

    Article  Google Scholar 

  3. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy. 2007;27(9):1219–30.

    Article  CAS  Google Scholar 

  4. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914–28.

    Article  CAS  Google Scholar 

  5. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285–92.

    Article  CAS  Google Scholar 

  6. Davern TJ 2nd, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology. 2006;130(3):687–94.

    Article  CAS  Google Scholar 

  7. Court MH, Freytsis M, Wang X, et al. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther. 2013;345(2):297–307.

    Article  CAS  Google Scholar 

  8. Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM, et al. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014;42(1):28–32.

    Article  CAS  Google Scholar 

  9. Heruth DP, Shortt K, Zhang N, Li DY, Zhang LQ, Qing Ye S. Genetic Association of Single nucleotide polymorphisms with acetaminophen-induced hepatotoxicity. J Pharmacol Exp Ther. 2018;367(1):95–100.

    Article  CAS  Google Scholar 

  10. Navarro SL, Chen Y, Li L, Li SS, Chang JL, Schwarz Y, et al. UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011;39(9):1650–7.

    Article  CAS  Google Scholar 

  11. Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res. 1996;20(1 Suppl):25A–8A.

    Article  CAS  Google Scholar 

  12. Bushel PR, Fannin RD, Gerrish K, Watkins PB, Paules RS. Blood gene expression profiling of an early acetaminophen response. Pharm J. 2017;17(3):230–6.

    CAS  Google Scholar 

  13. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91.

    Article  CAS  Google Scholar 

  14. Sidiropoulos K, Viteri G, Sevilla C, Jupe S, Webber M, Orlic-Milacic M, et al. Reactome enhanced pathway visualization. Bioinformatics. 2017;33(21):3461–7.

    Article  CAS  Google Scholar 

  15. Kusama H, Kon K, Ikejima K, Arai K, Aoyama T, Uchiyama A, et al. Sodium 4-phenylbutyric acid prevents murine acetaminophen hepatotoxicity by minimizing endoplasmic reticulum stress. J Gastroenterol. 2017;52(5):611–22.

    Article  CAS  Google Scholar 

  16. Yehia L, Niazi F, Ni Y, Ngeow J, Sankunny M, Liu Z, et al. Germline heterozygous variants in SEC23B are associated with Cowden syndrome and enriched in apparently sporadic thyroid cancer. Am J Hum Genet. 2015;97(5):661–76.

    Article  CAS  Google Scholar 

  17. Jiang J, Briede JJ, Jennen DG, et al. Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015;234(2):139–50.

    Article  CAS  Google Scholar 

  18. Wright SC, Canizal MCA, Benkel T, et al. FZD5 is a Galphaq-coupled receptor that exhibits the functional hallmarks of prototypical GPCRs. Sci Signal. 2018;11(559). https://doi.org/10.1126/scisignal.aar5536.

  19. Dadhania VP, Bhushan B, Apte U, Mehendale HM. Wnt/beta-catenin signaling drives thioacetamide-mediated heteroprotection against acetaminophen-induced lethal liver injury. Dose-Response. 2017;15(1):1559325817690287.

    Article  CAS  Google Scholar 

  20. Gerbal-Chaloin S, Dume AS, Briolotti P, et al. The WNT/beta-catenin pathway is a transcriptional regulator of CYP2E1, CYP1A2, and aryl hydrocarbon receptor gene expression in primary human hepatocytes. Mol Pharmacol. 2014;86(6):624–34.

    Article  Google Scholar 

  21. Cullen M, Perfetto SP, Klitz W, Nelson G, Carrington M. High-resolution patterns of meiotic recombination across the human major histocompatibility complex. Am J Hum Genet. 2002;71(4):759–76.

    Article  Google Scholar 

  22. Fannin RD, Gerrish K, Sieber SO, Bushel PR, Watkins PB, Paules RS. Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016;99(4):432–41.

    Article  CAS  Google Scholar 

  23. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117(5):1181–6.

    Article  CAS  Google Scholar 

  24. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717–20.

    Article  CAS  Google Scholar 

  25. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SGE. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2015;43(Database issue):D423–31.

    Article  CAS  Google Scholar 

Download references

Funding

The parent study was funded by Johnson and Johnson. A.A.M. received support from NIH 1R35GM124939 and NIH CTSI UL1 TR001082 for this work.

Author information

Authors and Affiliations

  1. Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA

    Andrew A. Monte, Brandon Sonn, Jessica Saben, Barry H. Rumack & Kennon J. Heard

  2. Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA

    Andrew A. Monte

  3. Skaggs School of Pharmacy, University of Colorado, Aurora, CO, USA

    Andrew A. Monte & Brandon Sonn

  4. Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority, Denver, CO, USA

    Andrew A. Monte, Barry H. Rumack, Kate M. Reynolds, Richard C. Dart & Kennon J. Heard

Authors
  1. Andrew A. Monte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brandon Sonn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessica Saben
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barry H. Rumack
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kate M. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard C. Dart
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kennon J. Heard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew A. Monte.

Ethics declarations

Conflict of Interest

None

Additional information

Supervising Editor: Mark B. Mycyk, MD

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(XLSX 30 kb)

ESM 2

(XLSX 45 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Monte, A.A., Sonn, B., Saben, J. et al. The Genomics of Elevated ALT and Adducts in Therapeutic Acetaminophen Treatment: a Pilot Study. J. Med. Toxicol. 17, 160–167 (2021). https://doi.org/10.1007/s13181-020-00815-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-020-00815-2

Keywords

Search

Navigation